Patient group
Erwachsene mit fortschreitenden Desmoidtumoren, die eine systemische Behandlung erfordern
Desmoid-Tumor, fortgeschritten
G-BA action
final resolution
2026-04-02
Evidence-checked summary
The G-BA found a hint of minor added benefit for Erwachsene mit fortschreitenden Desmoidtumoren, die eine systemische Behandlung erfordern. The G-BA issued a final resolution on 2026-04-02. The official page states that it took effect as follows: 02.04.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
Patient group
Erwachsene mit fortschreitenden Desmoidtumoren, die eine systemische Behandlung erfordern
Official case record
No inferred stages
Consultation record
2026-02-23
103 parsed turns
Oral hearing: Nirogacestat (Desmoid-Tumor, fortgeschritten)
Official Wortprotokoll · 14 pages
IQWiG comparison
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.
G-BA decisions
2026-04-02
final resolution
The G-BA found a hint of minor added benefit for Erwachsene mit fortschreitenden Desmoidtumoren, die eine systemische Behandlung erfordern. The G-BA issued a final resolution on 2026-04-02. The official page states that it took effect as follows: 02.04.2026. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources